(RTTNews) - Citius Oncology, Inc. (CTOR), the oncology subsidiary of Citius Pharmaceuticals Inc. (CTXR) announced the U.S. commercial launch of LYMPHIR, a new immunotherapy for adults with relapsed or ...
Dr. Van Morris presents the new evidence-based guideline on systemic therapy for localized anal squamous cell carcinoma. Dr. Morris discusses the key recommendations from the Expert Panel, including ...
Individual, group, and couples therapy are approaches that many turn to for family challenges. However, an effective, ...
—Building off of earlier findings, researchers sought to determine rates of neoadjuvant systemic therapy (NST) among U.S. women with cT1–2 N0 M0 HER2-positive breast cancer and identify factors ...
Stereotactic body radiotherapy (SBRT) alone achieves a 69.7% pooled 1- or 2-year systemic therapy-free survival rate across cancer types, with the highest rates seen in renal cell and prostate cancers ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — CD19 chimeric antigen receptor T-cell therapy led to remission, or ceased disease progression, over ...
Friedreich’s ataxia (FA), the most common form of hereditary ataxia, is an autosomal recessive neurodegenerative disorder affecting multiple organ systems, and causing cardiomyopathy, scoliosis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results